Genovis AB (publ.)
GEOVF
Other OTC7.34
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Fredrik Olsson
- Full Time Employees
- 37
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- ScheelevAegen 2 Lund Sweden 220 07
- IPO Date
- Oct 22, 2021
- Website
- genovis.com
- Similar Companies
- Business
- Genovis AB (publ.) (Ticker: GENO.ST; GEOVF) develops, manufactures and markets innovative enzyme-based tools and reagents for the biopharmaceutical, research and diagnostics industries, enabling faster development and quality control of biologics including antibodies, antibody-drug conjugates, gene therapies and genomics applications; core offerings span five primary product areas including SmartEnzymes such as FabRICATOR, GingisKHAN, FabALACTICA, IgGZERO, GlycINATOR, OpeRATOR, OglyZOR, SialEXO and IgMBRAZOR for precise antibody fragmentation, glycosylation analysis and protein characterization; BioProcess solutions featuring GlyCLICK and NIMT technologies for site-specific antibody labeling and conjugation; Genomics products like RNase inhibitors acquired via Sequrna; Gene Therapy tools; and Services encompassing antibody LC-MS analysis, custom fragmentation and bioprocess development support. The company serves global pharmaceutical giants, biotech firms and academic researchers in North America, Europe and Asia through direct sales, distributors and its wholly-owned U.S. subsidiary Genovis Inc., with additional presence in San Diego and Cambridge. Founded in 1999 and headquartered in Kävlinge, Sweden, Genovis lists on Nasdaq First North Growth Market and employs approximately 34 staff focused on R&D, production and commercialization of high-performance reagents. Recent developments include the full acquisition of Sequrna AB in July 2025 following a 25% stake purchase in 2024 to bolster genomics capabilities with RNase inhibitors now integrated into global research kits via expanded supply agreements; divestment of its antibody business to Leinco Technologies in August 2024; a June 2025 service agreement with evitria AG for fast LC-MS antibody characterization; licensing deals with Thermo Fisher Scientific for conjugation technologies supporting commercial-scale bioprocessing; and a major SEK 11 million order post-Q3 2025 from a global pharma firm for conjugation platform materials advancing a novel drug candidate, alongside SEK 88.7 million net sales for January-September 2025 reflecting 8-12% adjusted growth amid biotech market volatility.